Evidence map›Paper›PMID 34168440›Full record

ReviewInternational journal of chronic obstructive pulmonary disease2021

Update on Asthma-COPD Overlap (ACO): A Narrative Review.

Evgeni Mekov, Alexa Nuñez, Don D Sin, Masakazu Ichinose, Chin Kook Rhee, Diego Jose Maselli, Andréanne Coté, Charlotte Suppli Ulrik, François Maltais, Antonio Anzueto and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of chronic obstructive pulmonary disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  14. Article
  15. Asthma and respiratory comorbidities.The Journal of allergy and clinical immunology · 2025
    Review
  16. Article
  17. Plasma Levels of CXCL9 and MCP-3 are Increased in Asthma-COPD Overlap (ACO) Patients.International journal of chronic obstructive pulmonary disease · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 7 countries.

Evgeni MekovDepartment of Occupational Diseases, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria.
Alexa NuñezPneumology Department, Hospital Universitari Vall d´Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.ORCID 0000-0003-4067-0466
Don D SinCentre for Heart Lung Innovation, St. Paul's Hospital, Department of Medicine (Respiratory Division), University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-0756-6643
Masakazu IchinoseAcademic Center of Osaki Citizen Hospital, Miyagi, Japan.
Chin Kook RheeDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0000-0003-4533-7937
Diego Jose MaselliDivision of Pulmonary Diseases & Critical Care, University of Texas Health, South Texas Veterans Health Care System, San Antonio, TX, USA.
Andréanne CotéInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada.
Charlotte Suppli UlrikDepartment of Pulmonary Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark.ORCID 0000-0001-8689-3695
François MaltaisInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada.ORCID 0000-0002-6809-4651
Antonio AnzuetoDivision of Pulmonary Diseases & Critical Care, University of Texas Health, South Texas Veterans Health Care System, San Antonio, TX, USA.
Marc MiravitllesPneumology Department, Hospital Universitari Vall d´Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.ORCID 0000-0002-9850-9520
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESInstitut universitaire de cardiologie et de pneumologie de Québec · CAThe University of Texas Health Science Center at San Antonio · USMedical University of Sofia · BGOsaki Citizen Hospital · JPThe Catholic University of Korea Seoul St. Mary's Hospital · KRUniversity of British Columbia · CAUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although chronic obstructive pulmonary disease (COPD) and asthma are well-characterized diseases, they can coexist in a given patient. The term asthma-COPD overlap (ACO) was introduced to describe patients that have clinical features of both diseases and may represent around 25% of COPD patients and around 20% of asthma patients. Despite the increasing interest in ACO, there are still substantial controversies regarding its definition and its position within clinical guidelines for patients with obstructive lung disease. In general, most definitions indicate that ACO patients must present with non-reversible airflow limitation, significant exposure to smoking or other noxious particles or gases, together with features of asthma. In patients with a primary diagnosis of COPD, the identification of ACO has therapeutic implication because the asthmatic component should be treated with inhaled corticosteroids and some studies suggest that the most severe patients may respond to biological agents indicated for severe asthma. This manuscript aims to summarize the current state-of-the-art of ACO. The definitions, prevalence, and clinical manifestations will be reviewed and some innovative aspects, such as genetics, epigenetics, and biomarkers will be addressed. Lastly, the management and prognosis will be outlined as well as the position of ACO in the COPD and asthma guidelines.

Indexed as

AsthmaPulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesHumansLungSmokingAdrenal Cortex HormonesACOasthmabiomarkersCOPDepidemiologygeneticsprognosistreatment

Identifiers

PMID34168440
PMCPMC8216660
OpenAlexW3169950348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.